Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
about
Management of carcinoma in situ of the bladder: best practice and recent developmentsTargeted therapy in advanced bladder cancer: what have we learned?Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical applicationA place for precision medicine in bladder cancer: targeting the FGFRs.Drug-sensitive FGFR3 mutations in lung adenocarcinoma.The broad-spectrum receptor tyrosine kinase inhibitor dovitinib suppresses growth of BRAF-mutant melanoma cells in combination with other signaling pathway inhibitors.A Receptor Tyrosine Kinase Inhibitor, Dovitinib (TKI-258), Enhances BMP-2-Induced Osteoblast Differentiation In Vitro.Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More AttentionPhase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.New advances in genitourinary cancer: evidence gathered in 2014.Targeted therapies in bladder cancer: an overview of in vivo research.Targeting Signaling Transduction Pathways in Bladder Cancer.Emerging drugs for urothelial (bladder) cancer.Systemic therapy for metastatic bladder cancer in 2016 and beyond.Spectrum of genomic alterations in FGFR3: current appraisal of the potential role of FGFR3 in advanced urothelial carcinoma.Mutation Detection of Fibroblast Growth Factor Receptor 3 for Infiltrative Hepatocellular Carcinoma by Whole-Exome Sequencing.Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.A drug-drug interaction study to assess the effect of the CYP1A2 inhibitor fluvoxamine on the pharmacokinetics of dovitinib (TKI258) in patients with advanced solid tumors.Suppression of FGFR3- and MYC-dependent oncogenesis by tubacin: association with HDAC6-dependent and independent activities.A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells.CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
P2860
Q26775772-8B537E0C-2758-49E6-8F41-571A54AEC2E3Q27009469-33FDB813-C628-425F-9AB7-4DC55A9CD8EFQ28079309-9D4923A6-8326-4169-AD00-ADB8475E482BQ30249143-5F88060E-F810-4B4B-9AB9-A6264E9609BBQ33564782-7B88B411-062F-46FD-BBE9-E4CC8879333FQ35597799-6BB10B9C-5FC1-4109-9079-4FEF1C20BBC3Q36909540-89C4AA37-3ABC-4568-A75A-3E7A834D3932Q37527255-F2A5F4D8-00E5-4EB9-8227-6A4029A3B5F2Q37635256-29F12139-D4D9-468F-BCD3-742F5390CC0EQ38557894-CCE82040-7C0E-4671-A27F-D5466AB3B25DQ38590471-E34B82F2-44F2-454A-8014-B13EC91E1EBEQ38608540-6B069C92-BC47-4427-8D1C-77AE1EE04275Q38677414-63982811-0A11-453D-88EC-F1CE58B6D3A8Q38753358-199D4180-5DA7-4CD1-A43C-52F9B7DC66AEQ38810603-FED1887B-336B-4B22-A784-EB732A648439Q39036906-CB0896A3-D5AD-4EC0-903A-4F803F49C0BCQ42694284-9CAFD139-F8C4-4C42-ABE0-ABDB34CC2436Q48366406-7394DA5F-93EB-4140-A61C-2E81B6BD9676Q49456418-ECE5A0BE-83D5-4699-A352-F3FDF630E4C3Q52815341-0DC8E2B9-6E82-44F0-AFF0-D6FF14A1C6C0Q53142724-56DFF3A7-1986-4883-B538-8E5B4913C879Q58695446-B94655A6-291F-4659-87DB-2443447DF5CD
P2860
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@ast
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@en
type
label
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@ast
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@en
prefLabel
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@ast
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@en
P2093
P1476
Phase 2 trial of dovitinib in ...... advanced urothelial carcinoma.
@en
P2093
Christian Dittrich
Christopher J Sweeney
Cora N Sternberg
Dean Bajorin
Frederick E Millard
Ignacio Durán
Linda Cerbone
Matthew I Milowsky
Matthew Squires
Melissa Lochheed
P304
P356
10.1016/J.EJCA.2014.10.013
P577
2014-10-30T00:00:00Z